1. Réactions cutanées paradoxales sous traitement par tocilizumab.
- Author
-
Sparsa, L., Afif, N., Bularca, S., Fricker, A., Thiebault, S., Dahan, E., Wendling, D., Sibilia, J., and Ardizzone, M.
- Abstract
Introduction: Tocilizumab (TCZ) is a humanized antihuman interleukin (IL)-6 receptor antibody recommended for the treatment of moderate to severe active rheumatoid arthritis, adult-onset Still disease, Castleman disease and more recently, systemic juvenile idiopathic arthritis. Like anti-TNFα, rituximab and less frequently abatacept, TCZ can induce paradoxical cutaneous eruption like psoriasis with predominantly palmoplantar presentation. Case report: We report a 47-year-old woman with psoriastic arthritis who developed under anti-TNFα therapy and later under tocilizumab a paradoxical palmoplantar eruption. Conclusion: The specific underlying mechanisms of this side effect are unclear but relapse of these lesions seems to be observed with certain biological agents. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF